Form D · Pharmaceuticals

MediWound Ltd.

Yavne, L3 · CIK 0001593984

Offering snapshot reported Oct 6, 2022 · SEC filing

Reported sold
$17.2M
Offering amount: $17.2M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 22, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 6, 2022Initial$17,242,852No comparison10SEC filing
Oct 4, 2022Initial$13,257,148No comparison13SEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$982K
Finders' fees
$0
Form D file number
021-461038
Wainwright will also receive warrants to purchase 492,653 ordinary shares

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
H.C. Wainwright & Co., LLC375

Source: Form D, filed Oct 6, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Vickie R. Driver Director
David Fox Director
Ofer Gonen Executive
Boaz Gur Lavie Executive
Ety Klinger Director, Executive
Sharon Kochan Director
Sharon Malka Director
Nissim Mashiach Director
Yaron Meyer Executive
Tzvi Palash Executive
Lior Rosenberg Executive
Assaf Segal Director
Nachum (Homi) Shamir Director
Stephen T. Wills Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
42 Hayarkon Street
Yavne, L3, 8122745